Primary Non-invasive Cardiac Computed Tomography Versus Routine Invasive Angiography Prior to TAVI (CT-CA)
Primary Purpose
Severe Aortic Stenosis, Transcatheter Aortic Valve Implantation
Status
Unknown status
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Selective invasive angiography based on CT/CCTA imaging.
Procedure/Surgery: Invasive angiography
Sponsored by
About this trial
This is an interventional other trial for Severe Aortic Stenosis
Eligibility Criteria
Inclusion Criteria:
- Severe aortic stenosis (Peak transvalvular gradient of ≥ 40mmHg on TTE or stress Echo, Aortic valve area of < 1.0cm2)
- Symptoms suggestive of aortic stenosis (dyspnea, syncope, angina)
- Eligible for TAVI (Upon evaluation by a multidisciplinary team composed of at least one interventional cardiologist and one cardiothoracic surgeon)
Exclusion Criteria:
- Severe renal dysfunction Glomerular filtration rate < 30 ml/min.
- Severe left ventricular dysfunction LVEF ≤ 30%
- Recent coronary angiography ≤ 6months from randomization
- Recent PCI ≤ 6months from randomization
- Recent or active acute coronary syndrome (New or worsening angina with or without positive biomarkers or ECG changes).
Sites / Locations
- St. Paul's HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Selective invasive angiography based on CT/CCTA imaging
Invasive Cardiac Angiography
Arm Description
Patients will undergo selective invasive angiography based on CT/CCTA imaging. Decision to procede with additional invasive CA will be based on adequacy of CT/CCTA evaluation and likelihood of significant coronary artery disease.
Patients will undergo systematic invasive angiography.
Outcomes
Primary Outcome Measures
Number of patients enrolled in the study of all those that are eligible
This is the primary outcome for this pilot study to assess feasibility of a larger trial.
Secondary Outcome Measures
All-cause mortality
Myocardial Infarction
According to Valvular Academic Research Consortium-2 (VARC-2) criteria.
Periprocedural MI (≤72h post procedure).
Spontaneous MI.
Unplanned revascularization
Any unplanned coronary revascularization either with Percutaneous Coronary Intervention( PCI) or Coronary Artery Bypass Graft (CABG) post TAVI procedure.
Bleeding complication
According to VARC-2 criteria.
TAVI related ≤ 72h post TAVI
Coronary procedure related ≤ 72h post CA or PCI (if staged TAVI-PCI)
Device success
According to VARC-2 criteria.
Acute Kidney Injury
According to VARC-2 criteria.
Stroke
An acute episode of focal or global neurological dysfunction caused by the brain, spinal cord, or retinal vascular injury as assessed by a clinician and confirmed by at least one cerebral imaging study (CT or MRI). Stroke may be classified as ischaemic or haemorrhagic
Full Information
NCT ID
NCT03291925
First Posted
March 28, 2017
Last Updated
September 20, 2017
Sponsor
BC Centre for Improved Cardiovascular Health
Collaborators
Edwards Lifesciences
1. Study Identification
Unique Protocol Identification Number
NCT03291925
Brief Title
Primary Non-invasive Cardiac Computed Tomography Versus Routine Invasive Angiography Prior to TAVI
Acronym
CT-CA
Official Title
Primary Non-invasive Cardiac Computed Tomography Versus Routine Invasive Angiography Prior to TAVI: A Randomized Controlled Pilot Trial (CT-CA Study)
Study Type
Interventional
2. Study Status
Record Verification Date
September 2017
Overall Recruitment Status
Unknown status
Study Start Date
November 2016 (undefined)
Primary Completion Date
September 2019 (Anticipated)
Study Completion Date
September 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BC Centre for Improved Cardiovascular Health
Collaborators
Edwards Lifesciences
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This pilot study is a prospective, randomized, open-label trial that aims to assess the feasibility of comparing a primary Computed tomography/Cardiac computed tomography angiography (CT/CCTA) strategy (test arm) to a strategy combining routine use of CT/CCTA and invasive CA (control arm) prior to a Transcatheter aortic valve implantation (TAVI) procedure. The study will also estimate the rate of composite coronary adverse events (myocardial infarction, post procedural coronary revascularization and cardiovascular mortality) between the two arms at 90 days follow-up. The primary endpoint will be the feasibility of recruitment and compliance with the study protocol at 2 sites in Canada and 1 site in Denmark. Additional clinical endpoints including: all-cause death at 90 days post procedure, myocardial infarction at 90 days post procedure, unplanned PCI or CABG at 90 days post procedure, stroke at 90 days post procedure, CA and PCI related cumulative vascular complications events. This information will be used to inform the design of the definitive efficacy trial.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Severe Aortic Stenosis, Transcatheter Aortic Valve Implantation
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective, randomized, open-label trial.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Selective invasive angiography based on CT/CCTA imaging
Arm Type
Experimental
Arm Description
Patients will undergo selective invasive angiography based on CT/CCTA imaging. Decision to procede with additional invasive CA will be based on adequacy of CT/CCTA evaluation and likelihood of significant coronary artery disease.
Arm Title
Invasive Cardiac Angiography
Arm Type
Active Comparator
Arm Description
Patients will undergo systematic invasive angiography.
Intervention Type
Procedure
Intervention Name(s)
Selective invasive angiography based on CT/CCTA imaging.
Intervention Type
Procedure
Intervention Name(s)
Procedure/Surgery: Invasive angiography
Primary Outcome Measure Information:
Title
Number of patients enrolled in the study of all those that are eligible
Description
This is the primary outcome for this pilot study to assess feasibility of a larger trial.
Time Frame
18 months
Secondary Outcome Measure Information:
Title
All-cause mortality
Time Frame
90 days
Title
Myocardial Infarction
Description
According to Valvular Academic Research Consortium-2 (VARC-2) criteria.
Periprocedural MI (≤72h post procedure).
Spontaneous MI.
Time Frame
Peri-procedural (≤72h post procedure) and 90 days
Title
Unplanned revascularization
Description
Any unplanned coronary revascularization either with Percutaneous Coronary Intervention( PCI) or Coronary Artery Bypass Graft (CABG) post TAVI procedure.
Time Frame
90 days
Title
Bleeding complication
Description
According to VARC-2 criteria.
TAVI related ≤ 72h post TAVI
Coronary procedure related ≤ 72h post CA or PCI (if staged TAVI-PCI)
Time Frame
Peri-procedural (≤72h post procedure) and 90 days
Title
Device success
Description
According to VARC-2 criteria.
Time Frame
90 days
Title
Acute Kidney Injury
Description
According to VARC-2 criteria.
Time Frame
90 days
Title
Stroke
Description
An acute episode of focal or global neurological dysfunction caused by the brain, spinal cord, or retinal vascular injury as assessed by a clinician and confirmed by at least one cerebral imaging study (CT or MRI). Stroke may be classified as ischaemic or haemorrhagic
Time Frame
90 days
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Severe aortic stenosis (Peak transvalvular gradient of ≥ 40mmHg on TTE or stress Echo, Aortic valve area of < 1.0cm2)
Symptoms suggestive of aortic stenosis (dyspnea, syncope, angina)
Eligible for TAVI (Upon evaluation by a multidisciplinary team composed of at least one interventional cardiologist and one cardiothoracic surgeon)
Exclusion Criteria:
Severe renal dysfunction Glomerular filtration rate < 30 ml/min.
Severe left ventricular dysfunction LVEF ≤ 30%
Recent coronary angiography ≤ 6months from randomization
Recent PCI ≤ 6months from randomization
Recent or active acute coronary syndrome (New or worsening angina with or without positive biomarkers or ECG changes).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shirley Wong, PhD
Phone
604-682-2344
Email
3M@icvhealth.ubc.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jonathon Leipsic, MD
Organizational Affiliation
St. Paul's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Paul's Hospital
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V6Z1Y6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shirley Wong, PhD
Phone
604-682-2344
Ext
65676
Email
3M@icvhealth.ubc.ca
First Name & Middle Initial & Last Name & Degree
Leipsic Jonathon, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Primary Non-invasive Cardiac Computed Tomography Versus Routine Invasive Angiography Prior to TAVI
We'll reach out to this number within 24 hrs